A clinical trial investigated a novel single wave assessment for evaluating cardiac dysfunction and metabolic syndrome in patients with malignant neoplasms. The study enrolled 159 participants and utilized a hand-held device to measure left ventricular ejection fraction, assessing heart pumping efficiency and arterial stiffness via pulse wave velocity. Correlative studies were conducted alongside laboratory biomarker analysis.
Primary Research Objectives
Primary objectives focused on establishing the relationship between insulin resistance, quantified by the single wave application, and inflammation markers associated with metabolic syndrome in cancer patients. The study sought to determine the mean and standard deviation of this measurement in patients with and without the syndrome, informing the design of future, larger studies. **II**
Secondary Assessment and Methodology
Secondary objectives involved comparing the single wave measurement of left ventricular ejection fraction with standard 2-dimensional echocardiography. Patients were positioned with the single wave application near the carotid region of the neck to facilitate measurement. This research explored the potential of the single wave assessment as a tool for early detection and risk stratification in cancer patients.